Therapeutic Asset Ratings

502 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
(1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil 1:4 Non-Small Cell Lung Carcinoma	AstraZeneca	P3	CCC (54)
azd5305 Breast Cancer	AstraZeneca	P3	CCC (54)
azd5335 Ovarian Carcinoma	AstraZeneca	P3	CCC (54)
Dapagliflozin Cirrhosis Of Liver	AstraZeneca	P2	CCC (54)
azd7789 Non-Small Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (54)
azd0901 Gastroesophageal Junction Adenocarcinoma	AstraZeneca	P2	CCC (53)
azd8965 Idiopathic Pulmonary Fibrosis	AstraZeneca	P2	CCC (53)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Urothelial Carcinoma	AstraZeneca	P2	CCC (53)
Datopotamab Deruxtecan Urothelial Carcinoma	AstraZeneca	P2	CCC (53)
Durvalumab Soft Tissue Neoplasm	AstraZeneca	P2	CCC (53)
Eplontersen Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	AstraZeneca	P2	CCC (53)
gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV3-1507 (86.9%)--(IGHD) -IGHJ101(90.9%), CDR-IMGT [8.10.9] (26-33.51-60.99-107))(1-118) -Homo sapiens IGHG101 (100%), G1m17,1 CH1K120, CH3 D12, L14 (CH1 K120 (215) (119-216),hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain humanized (1'-220') [V-KAPPA (Homo sapiens IGKV2-2401 (90.0%)-IGKJ201 (100%), CDR-IMGT [11.3.10] (27-37.55-57.94-103)) (1'-113') -Homo sapiens IGKC01 (100%), Km3, A45.1 (159), V101 (197) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa Soft Tissue Neoplasm	AstraZeneca	P2	CCC (53)
PREDNISONE TABLETS Urothelial Carcinoma	AstraZeneca	P2	CCC (53)
Rilvegostomig Urothelial Carcinoma	AstraZeneca	P2	CCC (53)
Trastuzumab Deruxtecan Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer	AstraZeneca	P2	CCC (53)
Trastuzumab Deruxtecan Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer	AstraZeneca	P2	CCC (53)
Volrustomig Urothelial Carcinoma	AstraZeneca	P2	CCC (53)
ZD4054 Cirrhosis Of Liver	AstraZeneca	P2	CCC (53)
azd5991 Acute Myeloid Leukemia	AstraZeneca	P1/2	CCC (53)
Durvalumab Peritoneal Neoplasm	AstraZeneca	P1/2	CCC (53)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Peritoneal Neoplasm	AstraZeneca	P1/2	CCC (53)
Capecitabine Endometrial Carcinoma	AstraZeneca	P2	CCC (52)
Capecitabine Metastatic Prostate Carcinoma	AstraZeneca	P2	CCC (52)
Datopotamab Deruxtecan Endometrial Carcinoma	AstraZeneca	P2	CCC (52)
Datopotamab Deruxtecan Gastric Cancer	AstraZeneca	P2	CCC (52)

Showing 126 to 150 of 502 assets

PreviousPage 6 of 21Next